Trekrezan in adults and adolescents with acute respiratory viral infections
Comparison in people · 2023
- What was studied
- 172 outpatients. Trekrezan plus symptomatic care: 75 adults and 47 adolescents. Symptomatic care: 30 adults and 20 adolescents. All 30 adult controls came from the 2021 Frolova study.
- Main finding
- Adolescent fever lasted 2.5 days less with Trekrezan. At days 3–5, fatigue persisted in 47.3% of treated adults and 70% of adult controls drawn from the earlier study.
Reported findings and study design
Postmarketing comparison using patient diaries and clinical assessments at days 3–5 and 7–8. Positive influenza or SARS-CoV-2 tests were exclusion criteria.
Population or model 172 outpatients. Trekrezan plus symptomatic care: 75 adults and 47 adolescents. Symptomatic care: 30 adults and 20 adolescents. All 30 adult controls came from the 2021 Frolova study.
Dose, route and schedule
Oral Trekrezan 600 mg on day 1, then 200 mg/day for seven days (2,000 mg total).
Protocol source ↗ · Original PDF, study design, cohort attribution, Figures 1–2 and clinical outcome tables.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fever duration in adolescents | 2.5 days shorter with Trekrezan | 47 treated vs 20 symptomatic-care controls · p≤0.05 |
| Adults with prominent symptoms and fever | 58% vs 90%, down from 100% in both groups | Days 3–5 · Figure 1A, p=0.001 |
| Asthenia in adults | 47.3% vs 70% | Days 3–5 · Figure 1B, p=0.002 |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- The open observational study mixed prospective data with historical adult controls. The 172 reported participant records include 30 already reported in Frolova 2021.
Related publications may describe some of the same participants or experiments.
Source details
Original PDF, study design, cohort attribution, Figures 1–2 and clinical outcome tables.
Sources checked
Citation
E. V. Esaulenko, K. E. Novak, A. D. Ibrokhimova, M. G. Pozdnyakova, A. L. Balashov, E. Y. Noginova. Trekrezan in adults and adolescents with acute respiratory viral infections Russian Medical Inquiry. 2023;7(11):718–724.
Study source ↗ · DOI 10.32364/2587-6821-2023-7-11-3 · Bibliography entry · Link to this summary